Correlation between expression of ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 and programmed cell death-ligand 1 in non-small cell lung cancer

CHEN Xiuhong; LI Kun; JIN Shuang; ZHANG Zhongmian

doi:10.7619/jcmp.20213152

Journal of Clinical Medicine in Practice > 2021 > 25(23): 31-36. > DOI: 10.7619/jcmp.20213152

CHEN Xiuhong, LI Kun, JIN Shuang, ZHANG Zhongmian. Correlation between expression of ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 and programmed cell death-ligand 1 in non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 31-36. DOI: 10.7619/jcmp.20213152

Citation:

PDF (1737 KB)

Correlation between expression of ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 and programmed cell death-ligand 1 in non-small cell lung cancer

Department of Oncology, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450014

More Information

Received Date: August 04, 2021
Available Online: December 20, 2021

Graphical Abstract

Abstract

Abstract

Objective
To explore the correlation between ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 (OTUB1) and programmed cell death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC).
Methods
Differences of OTUB1 mRNA between NSCLC and corresponding non-tumor normal tissues in the Cancer Genome Atlas (TCGA) were analyzed. The correlation on mRNA expression between OTUB1 and PD-L1 in NSCLC in Gene Expression Profiling Interactive Analysis (GEPIA) was discussed. The protein expressions of OTUB1 and PD-L1 in 46 cases of NSCLC and 41 cases of corresponding non-tumor normal tissues were detected by immunohistochemistry, and the clinical case data and follow-up data were collected. The expression difference of OTUB1 between cancer tissues and adjacent tissues, the correlations between OTUB1 and PD-L1 as well as clinicopathological features, and the predictive significance for recurrence free survival (RFS) were analyzed.
Results
There were significant differences in mRNA and protein expressions of OTUB1 between NSCLC and corresponding non-tumor normal tissues (P < 0.05). There was no correlation in mRNA expression between OTUB1 and PD-L1 in NSCLC tissues (P>0.05), but there was a correlation in protein expression between OTUB1 and PD-L1 (P=0.029). OTUB1 was correlated with TNM staging (P=0.039), but had no correlation with age, history of smoking, degree of differentiation, number of metastatic lymph nodes and pathological type (P>0.05). Kaplan-Meier analysis showed that TNM staging (P < 0.001), the number of metastatic lymph nodes (P=0.001) and the degree of differentiation (P=0.042)were the influencing factors of RFS. The median RFS of negative and positive OTUB1 were 18 months and 19 months, respectively, and there was no significant difference (P>0.05). COX multivariate analysis showed that the degree of differentiation (P=0.005) and TNM staging (P=0.006) were the independent risk factors for RFS.
Conclusion
The mRNA and protein expression levels of OTUB1 in NSCLC tissue are higher than those in corresponding non-tumor normal tissues. In terms of protein level, OTUB1 is positively correlated with PD-L1. OTUB1 expression is related to TNM staging.

FullText(HTML)

References (27)

References

[1]	BARTA J A, POWELL C A, WISNIVESKY J P. Global epidemiology of lung cancer[J]. Ann Glob Heal, 2019, 85(1): 8. doi: 10.5334/aogh.2419
[2]	OSMANI L, ASKIN F, GABRIELSON E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy[J]. Semin Cancer Biol, 2018, 52(pt 1): 103-109. http://www.ncbi.nlm.nih.gov/pubmed/29183778
[3]	ZOU W, WOLCHOK J D, CHEN L. PD-L1(B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations[J]. Sci Transl Med, 2016, 8(328): 328rv4. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859220/pdf/nihms-780239.pdf
[4]	EIKAWA S, NISHIDA M, MIZUKAMI S, et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin[J]. PNAS, 2015, 112(6): 1809-1814. doi: 10.1073/pnas.1417636112
[5]	YANG Y, HSU J M, SUN L, et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth[J]. Cell Res, 2019, 29(1): 83-86. doi: 10.1038/s41422-018-0124-5
[6]	ZHANG J, BU X, WANG H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance[J]. Nature, 2018, 553(7686): 91-95. doi: 10.1038/nature25015
[7]	LIM S O, LI C W, XIA W, et al. Deubiquitination and stabilization of PD-L1 by CSN5[J]. Cancer Cell, 2016, 30(6): 925-939. doi: 10.1016/j.ccell.2016.10.010
[8]	DENG S, ZHOU X, XU J. Checkpoints under traffic control: from and to organelles[J]. Adv Exp Med Biol, 2020, 1248: 431-453. doi: 10.1007/978-981-15-3266-5_18
[9]	FRAME S, COHEN P. GSK3 takes centre stage more than 20 years after its discovery[J]. Biochem J, 2001, 359(pt 1): 1-16. http://www.biochemj.org/content/359/1/1.full-text.pdf
[10]	YANG Y, HSU J M, SUN L, et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth[J]. Cell Res, 2019, 29(1): 83-86. doi: 10.1038/s41422-018-0124-5
[11]	ZHU Q, FU Y, LI L, et al. The functions and regulation of Otubains in protein homeostasis and diseases[J]. Ageing Res Rev, 2021, 67: 101303. doi: 10.1016/j.arr.2021.101303
[12]	ZHU D, XU R, HUANG X, et al. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1[J]. Cell Death Differ, 2021, 28(6): 1773-1789. doi: 10.1038/s41418-020-00700-z
[13]	TOMCZAK K, CZERWI? SKA P, WIZNEROWICZ M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge[J]. Contemp Oncol: Pozn, 2015, 19(1a): A68-A77. http://www.scienceopen.com/document_file/ac4bb8d0-842c-4c65-924e-c0b532b5ab9c/PubMedCentral/ac4bb8d0-842c-4c65-924e-c0b532b5ab9c.pdf
[14]	TANG Z, LI C, KANG B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(w1): W98-W102. doi: 10.1093/nar/gkx247
[15]	ZHOU Y, WU J, FU X, et al. OTUB1 promotes metastasis and serves as a marker of poor prognosis in colorectal cancer[J]. Mol Cancer, 2014, 13: 258. doi: 10.1186/1476-4598-13-258
[16]	WENG W, ZHANG Q, XU M, et al. OTUB1 promotes tumor invasion and predicts a poor prognosis in gastric adenocarcinoma[J]. Am J Transl Res, 2016, 8(5): 2234-2244. http://ajtr.org/files/ajtr0023747.pdf
[17]	KARUNARATHNA U, KONGSEMA M, ZONA S, et al. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance[J]. Oncogene, 2016, 35(11): 1433-1444. doi: 10.1038/onc.2015.208
[18]	IGLESIAS-GATO D, CHUAN Y C, JIANG N, et al. Erratum: OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo[J]. Mol Cancer, 2015, 14: 88. doi: 10.1186/s12943-015-0341-1
[19]	WANG Y, WANG H, YAO H, et al. Regulation of PD-L1: emerging routes for targeting tumor immune evasion[J]. Front Pharmacol, 2018, 9: 536. doi: 10.3389/fphar.2018.00536
[20]	ALTUN M, WALTER T S, KRAMER H B, et al. The human otubain2-ubiquitin structure provides insights into the cleavage specificity of poly-ubiquitin-linkages[J]. PLoS One, 2015, 10(1): e0115344. doi: 10.1371/journal.pone.0115344
[21]	WIENER R, ZHANG X, WANG T, et al. The mechanism of OTUB1-mediated inhibition of ubiquitination[J]. Nature, 2012, 483(7391): 618-622. doi: 10.1038/nature10911
[22]	FEDCHENKO N, REIFENRATH J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue-a review[J]. Diagn Pathol, 2014, 9: 221. doi: 10.1186/s13000-014-0221-9
[23]	THOMPSON R H, KUNTZ S M, LEIBOVICH B C, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up[J]. Cancer Res, 2006, 66(7): 3381-3385. doi: 10.1158/0008-5472.CAN-05-4303
[24]	HSU M C, HSIAO J R, CHANG K C, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma[J]. Mod Pathol, 2010, 23(10): 1393-1403. doi: 10.1038/modpathol.2010.130
[25]	HAMANISHI J, MANDAI M, IWASAKI M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer[J]. PNAS, 2007, 104(9): 3360-3365. doi: 10.1073/pnas.0611533104
[26]	BAIETTI M F, SIMICEK M, ABBASI ASBAGH L, et al. OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination[J]. EMBO Mol Med, 2016, 8(3): 288-303. doi: 10.15252/emmm.201505972
[27]	LI Y, SUN X X, ELFERICH J, et al. Monoubiquitination is critical for ovarian tumor domain-containing ubiquitin aldehyde binding protein 1(Otub1) to suppress UbcH5 enzyme and stabilize p53 protein[J]. J Biol Chem, 2014, 289(8): 5097-5108. doi: 10.1074/jbc.M113.533109

[1]	JU Shande, GUO Zhiqiang, WANG Yongfang, YU Yang, WANG Yanyan. Effect of obstructive sleep apnea syndrome on non-arteritic anterior ischemic optic neuropathy[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 49-51, 58. DOI: 10.7619/jcmp.20232194
[2]	LIU Yihan, ZHU Ning, XUE Mengzhou, ZHU Hongshan, CHEN Chen. Effect of sleep status on mood and daytime fatigue in patients with obstructive sleep apnea hypopnea syndrome complicating with stroke[J]. Journal of Clinical Medicine in Practice, 2023, 27(17): 77-81. DOI: 10.7619/jcmp.20231598
[3]	YANG Ping, LIU Rui, XUE Yani, WANG Yi, ZHANG Min, CHEN Yongjin, LI Qiang. Effect of Er: YAG laser in the treatment of patients with obstructive sleep apnea hypopnea syndrome[J]. Journal of Clinical Medicine in Practice, 2023, 27(17): 1-4, 12. DOI: 10.7619/jcmp.20231483
[4]	LI Ning, WU Feng, HU Tao. Research progress of hypoxia-inducible factor-1α and obstructive sleep apnea associated hypertension[J]. Journal of Clinical Medicine in Practice, 2023, 27(7): 138-142. DOI: 10.7619/jcmp.20223407
[5]	DONG Zhishuang, LI Guangyuan, LIU Wen, KONG Fanxin, WANG Yonghuai, MA Chunyan. Research progress on evaluation of arterial stiffness by pulse wave velocity in patients with obstructive sleep apnea hypopnea syndrome[J]. Journal of Clinical Medicine in Practice, 2022, 26(5): 135-138. DOI: 10.7619/jcmp.20213566
[6]	CAO Sipei, WANG Hongmei, WU Feng. Value of nocturnal pulse oxygen saturation in predicting patients with obstructive sleep apnea hypopnea syndrome complicating with type 2 diabetes[J]. Journal of Clinical Medicine in Practice, 2022, 26(5): 75-78, 85. DOI: 10.7619/jcmp.20214030
[7]	CHEN Yan, WANG Xiaoqing, HAO Hairong, BAI Feng, ZHANG Yong, CHENG Liang, HU Wen. Effect of exenatide on hypoxia status of patients with type 2 diabetes mellitus complicated with obstructive sleep apnea hypopnea syndrome[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 77-81. DOI: 10.7619/jcmp.202010019
[8]	SHI Cuiling. Clinical observation of life style intervention for patients with obstructive sleep apnea hypopnea syndrome[J]. Journal of Clinical Medicine in Practice, 2017, (14): 130-132,149. DOI: 10.7619/jcmp.201714039
[9]	FENG Yongjun, LIN Chong, ZENG Chunrong, WU Xiangmin. Changes and significance of hemorheological indexes of patients with obstructive sleep apnea hypopnea syndrome[J]. Journal of Clinical Medicine in Practice, 2015, (5): 11-14. DOI: 10.7619/jcmp.201505004
[10]	YU Jieming, SUN Xiuli, GAO Ning. Clinical observation of surgeries on treatment of children with obstructive sleep apnea hypopnea syndrome[J]. Journal of Clinical Medicine in Practice, 2014, (15): 59-62. DOI: 10.7619/jcmp.201415018

Cited By

Cited by

Periodical cited type(6)

1.	钱新民，丁兆生，李佟，徐春丽，张万权，周芳. 奥沙西泮联合度洛西汀治疗抑郁症的临床效果. 临床合理用药. 2024(08): 71-73 .
2.	吴书清，黄蕾，王丽君，秦艳，孙英，闵凌峰，刘异凡，刘彦. 光电容积脉搏波描记法对重症患者合并阻塞性睡眠呼吸暂停综合征的诊断价值. 实用临床医药杂志. 2024(11): 1-5 . 本站查看
3.	原改兰，罗少亚，张兵兵. 分析NSCLC患者血清学指标与OSAS之间的相关性. 罕少疾病杂志. 2024(08): 45-46 .
4.	胡佩瑞，张亚倩，阎妍，陈玺. 阻塞性睡眠呼吸暂停低通气综合征患者HIF-1a、IGF-1及HGF的表达与意义. 分子诊断与治疗杂志. 2023(06): 939-942 .
5.	朱淑芹，邓旭，魏吉林，刘治国. 中性粒细胞与淋巴细胞比值、胱抑素C在2型糖尿病周围神经病变中的诊断价值. 国际检验医学杂志. 2023(14): 1709-1712 .
6.	孙雅琪. 睡眠呼吸暂停低通气综合征筛查中动态心电图推导呼吸曲线技术的应用效果. 中国医疗器械信息. 2022(22): 58-60 .

Other cited types(1)

Get Citation

PDF

XML

Article views (296) PDF downloads (14) Cited by(7)

Turn off MathJax

Article Contents

Abstract

References

Correlation between expression of ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 and programmed cell death-ligand 1 in non-small cell lung cancer